MedPath

Testosterone

Generic Name
Testosterone
Brand Names
Androderm, Androgel, Axiron, Fortesta, Natesto, Striant, Testim, Testopel, Vogelxo
Drug Type
Small Molecule
Chemical Formula
C19H28O2
CAS Number
58-22-0
Unique Ingredient Identifier
3XMK78S47O
Background

Testosterone is a steroid sex hormone indicated to treat primary hypogonadism and hypogonadotropic hypogonadism. Testosterone antagonizes the androgen receptor to induce gene expression that causes the growth and development of masculine sex organs and secondary sexual characteristics.

Testosterone was isolated from samples and also synthesized in 1935.

Indication

Testosterone is indicated to treat primary hypogonadism and hypogonadotropic hypogonadism.

Associated Conditions
Hypergonadotropic Hypogonadism, Hypogonadotrophic Hypogonadism, Idiopathic Hypogonadotropic Hypogonadism, Puberty, Delayed, Inoperable, metastatic Breast cancer
Clinical Trials
Related News

Effects of Early Testosterone Gel Administration on Physical Performance in the Critically Ill

Phase 2
Recruiting
Conditions
Critical Illness
Interventions
Drug: Placebo
Diagnostic Test: Physical performance
Diagnostic Test: Muscle strength
Diagnostic Test: Muscular mass
Diagnostic Test: Oxygen muscular consumption
First Posted Date
2023-04-24
Last Posted Date
2023-10-02
Lead Sponsor
University Hospital, Clermont-Ferrand
Target Recruit Count
600
Registration Number
NCT05825092
Locations
🇫🇷

Service de Medecine Intensive et Réanimation CHU de Bordeaux Hopital Pellegrin, Bordeaux, France

🇫🇷

Service d'Anesthésie et Réanimation Centre Jean-Perrin, Clermont-Ferrand, France

🇫🇷

Service de Médecine Intensive et Réanimation (MIR), CHU Clermont-Ferrand, Clermont-Ferrand, France

and more 2 locations

The Influence of Testosterone on Experimental Pain Perception

Early Phase 1
Completed
Conditions
Acute Pain
Interventions
Other: Placebo Syrup
First Posted Date
2023-03-23
Last Posted Date
2024-08-05
Lead Sponsor
University of New Mexico
Target Recruit Count
20
Registration Number
NCT05781685
Locations
🇺🇸

University of New Mexico, Albuquerque, New Mexico, United States

Exploring the Relationship Between Androgen Metabolism, Metabolic Disease and Skeletal Muscle Energy Balance in Men

Not yet recruiting
Conditions
Testosterone Deficiency
Metabolic Disturbance
Cardiovascular Diseases
Diabetes
Hypogonadism, Male
Androgen Deficiency
Metabolic Disease
Obesity
NAFLD
Prostate Cancer
Interventions
First Posted Date
2023-03-17
Last Posted Date
2023-03-17
Lead Sponsor
Royal College of Surgeons, Ireland
Target Recruit Count
60
Registration Number
NCT05773183
Locations
🇮🇪

Beaumont Hospital, Dublin 9, Ireland

Does Testosterone Therapy Improve Patient-Reported Outcomes in Age-Related Testosterone Deficient Patients Undergoing Total Hip Replacement: A Randomized-Controlled Trial

Phase 3
Withdrawn
Conditions
Arthroplasty, Replacement, Hip
Interventions
Other: No Testosterone Therapy
First Posted Date
2023-02-10
Last Posted Date
2023-02-10
Lead Sponsor
American Hip Institute
Registration Number
NCT05722301
Locations
🇺🇸

American Hip Institute Research Foundation, Des Plaines, Illinois, United States

Early Mental Response - The EMRE Study

Not Applicable
Recruiting
Conditions
Gender Identity
Gender Issues
Gender Dysphoria
Interventions
Other: Placebo treatment
First Posted Date
2022-12-14
Last Posted Date
2023-03-08
Lead Sponsor
Karolinska University Hospital
Target Recruit Count
70
Registration Number
NCT05649605
Locations
🇸🇪

Karolinska Universitetssjukhuset, ANOVA, Stockholm, Sweden

Sex Steroids Balance for Metabolic and Reproductive Health in Klinefelter Syndrome

Phase 3
Recruiting
Conditions
Klinefelter Syndrome
Interventions
First Posted Date
2022-10-19
Last Posted Date
2024-01-05
Lead Sponsor
Georgios Papadakis
Target Recruit Count
150
Registration Number
NCT05586802
Locations
🇨🇭

Service of Endocrinology, Diabetes & Metabolism, Lausanne, Switzerland

Effect of Dose Fractionation of Testosterone Cypionate on Transgender Men with Erythrocytosis

Not Applicable
Completed
Conditions
Testosterone
Transsexualism
Hematologic Diseases
Interventions
First Posted Date
2022-08-04
Last Posted Date
2025-03-28
Lead Sponsor
University of Sao Paulo
Target Recruit Count
46
Registration Number
NCT05487794
Locations
🇧🇷

Faculdade de Medicina de Ribeirão Preto - FMRP-USP, Ribeirão Preto, SP, Brazil

Natesto Testosterone Nasal Gel for Hypogonadal Men

Phase 4
Withdrawn
Conditions
Erectile Dysfunction
Sexual Dysfunction
Interventions
Drug: Placebo
First Posted Date
2022-08-02
Last Posted Date
2022-12-21
Lead Sponsor
University of Utah
Registration Number
NCT05484167
Locations
🇺🇸

University of Utah, Division of Urology, Salt Lake City, Utah, United States

Perioperative Testosterone Replacement Therapy in Sarcopenic Male Colorectal Cancer Patients

Conditions
Perioperative Care
Colorectal Cancer
Testosterone Replacement Therapy
Sarcopenia
Hypogonadism, Male
First Posted Date
2022-05-10
Last Posted Date
2022-05-10
Lead Sponsor
London North West Healthcare NHS Trust
Target Recruit Count
30
Registration Number
NCT05367284
Locations
🇬🇧

London North West University Healthcare NHS Trust, London, United Kingdom

Testosterone & Tamoxifen Trial

Not Applicable
Terminated
Conditions
Male Breast Cancer
Interventions
First Posted Date
2021-12-14
Last Posted Date
2024-08-09
Lead Sponsor
University Medical Center Groningen
Target Recruit Count
5
Registration Number
NCT05156606
Locations
🇳🇱

UMCG, Groningen, Netherlands

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy